
Expert AAV Development
& cGMP Manufacturing
At Forge, better manufacturing isn’t a benchmark—it’s a mindset. Through innovative technologies and continuous improvement, we deliver end-to-end AAV manufacturing services. Any stage. Any serotype. Built around your journey.

Your AAV Partner from Idea to Impact
Gene therapy manufacturing takes more than infrastructure. It takes the right team, the right platform, and a partner at every step. Forge offers research-grade production, process development, and cGMP manufacturing alongside in-house plasmid production, molecular development, analytics, quality, fill-finish, stability, and regulatory support—all fully integrated to streamline your path forward.
AAV Manufacturing
that Meets You Where You Are
Whether you’re optimizing your AAV process or ready to scale, Forge offers manufacturing paths designed to meet you where you are.
advanced AAV platform
Accelerate with Our FUEL™ Platform
Still developing your process and need a manufacturing solution to streamline your path? Forge’s FUEL™ platform offers a powerful head start—an innovative AAV manufacturing foundation built to help you scale efficiently. With advanced technologies, proven processes, and flexible, product-specific optimizations, FUEL™ can increase productivity and recovery while maintaining product quality.
discovery support
Blaze Research-Grade AAV Production
Early-stage developers need fast, scalable access to research-grade material. Enter Blaze, our research-grade AAV production at 1–40L. Blaze is ideal for discovery work like material generation for proof-of-concept studies or assessing vector manufacturability. With a scalable process and Forge’s proprietary technologies, it gives early-stage developers confidence in a seamless path to cGMP.
*Forge also offers research-grade plasmid cell banking and manufacturing services.

Process, Perfected
Process Development
No two gene therapy programs are alike. That’s why our process development services are built around product-specific optimizations to drive success and cGMP readiness. With deep experience across natural and novel AAV serotypes and a broad range of indications, we’ve mapped 50+ upstream and downstream studies to help optimize yield, purity, and efficiency. Every strategy is tailored with time, cost, and long-term impact in mind.
*Forge also offers research-grade plasmid cell banking and manufacturing services.

Consistency
cGMP Production
Maintaining consistency at cGMP scale is vital to program success, and you need a manufacturing partner who can reliably scale with you. Forge’s cGMP production—ranging from 50 to 5,000L—is designed for scalability, efficiency, and repeatable manufacturing success. Backed by deep technical expertise, our team leverages single-use technologies and optimized closed-system processes to produce larger batches with high throughput and minimal variability.
*Forge offers GMP Pathway (Phase I/II) and cGMP (Phase I-Commercial) plasmid cell banking and manufacturing services.

Seamless Technology Transfer
Have a locked process and need a partner for manufacturing execution? Forge offers collaborative, systematic tech transfer services backed by deep AAV expertise. With in-house process knowledge and access to a wide range of development and production scales, we’re built to support your success from transfer through execution.
In-house advantage
Analytical Development & Quality Control
At Forge, precise analytics and quality aren’t add-ons—they’re the foundation of everything we do. We offer 25+ in-house AAV assays to accelerate characterization and release. Our integrated QC and QA framework, supported by cGMP compliance and connected systems, ensures consistent, compliant quality manufacturing from start to finish.
*

Precision
Fill-Finish
Forge offers a range of fill-finish services to meet the needs of your program. We provide drug product fill options across automated, semi-automated, and manual operations, designed to accommodate varying batch sizes, container types, and fill volumes to suit your product requirements.

stability starts here
Stability
For gene therapy developers, providing product stability is a critical step toward clinical and commercial success. That’s why Forge offers long-term frozen and accelerated stability testing as well as device compatibility studies, generating product-specific data from early-phase lots to evaluate the stability of the drug product across its intended use and storage conditions.

regulatory & molecular development
Supporting Services
Forge was built to be more than a manufacturer. We are a true partner, offering services and expertise to support your program from early development through cGMP and beyond. Our molecular development team provides early-phase guidance such as GOI construct evaluation for manufacturability. Our regulatory team works closely with clients to shape program strategy, offering support for agency interactions, CMC/IMPD documentation, and more. With AAV and plasmid Drug Master Files maintained in the U.S. and Canada, we deliver comprehensive support throughout the regulatory process.

The hearth
Our Industry-Leading Production Facility
To bring gene therapies to patients, you need a facility built for scale, flexibility, global readiness—and unwavering compliance. The Hearth, Forge’s 200,000+ sq. ft. GMP facility, is one of the largest manufacturing sites dedicated to AAV. With 20 cGMP suites and bioreactors ranging from 50 to 5,000L, it’s intentionally designed to increase throughput and support efficient production.
Proven by Programs Like Yours
These numbers reflect more than experience. They represent the trusted partnerships built by the clients who choose us.
50+
More than 50 clients supported across all stages
500
Over 500 batches manufactured to date
97%
97% of clients use our technologies
35+
Expertise in supporting more than 35 indications
Frequently Asked Questions
Does Forge Biologics provide AAV CRO services?
While we don’t provide traditional CRO services, like preclinical or clinical trial management, we work closely with clients to support their manufacturing strategy throughout the development lifecycle and maintain preferred partnerships with CROs that we can connect our clients to as needed.
How quickly can Forge deliver a GMP batch?
Timelines for GMP batch delivery are highly dependent on the specifics of your program, including vector design, process readiness, and scope of work. Connect with our Client Development team to discuss your program and receive a more detailed scope of work based on your program needs.
Can Forge help with IND filings and regulatory guidance?
Yes, Forge offers regulatory guidance and support to assist with IND filings and broader regulatory strategy. As part of our standard regulatory services, we provide:
*A Letter of Authorization to cross-reference our Drug Master File (DMF)
*A Module 3 guide outlining sponsor vs. DMF responsibilities
*Assistance with written responses to agency information requests
*A Site Master File to support regulatory submissions
We also offer regulatory strategy consulting that spans the full development program, including:
*Ad hoc consultation tailored to your specific program needs
*Review or authoring of IND and other regulatory documentation
*Participation in meetings with health authorities
*Strategic input beyond the IND stage
What differentiates Forge’s AAV manufacturing from other CDMOs?
Gene therapy developers need more than a manufacturer, they need a true partner. At Forge, we were founded by developers, for developers, with deep AAV manufacturing expertise and a commitment to solving the unique challenges of gene therapy development and manufacturing. Our focus in AAV, robust process development, and investment in manufacturing technology, set us apart.
Does Forge offer fill/finish services?
Yes, Forge offers a range of fill-finish services to meet the needs of your program. We provide customizable drug product fill options across automated, semi-automated, and manual operations, designed to accommodate varying batch sizes, container types, and fill volumes to suit your product requirements.
Do you perform all manufacturing and development work in-house?
Yes. All development and manufacturing work is performed at the Hearth, Forge’s 200,000 sq. ft. custom-designed cGMP facility dedicated to AAV viral vector manufacturing in Grove City, Ohio.
How many assays does Forge perform in-house?
Forge offers over 25 AAV assays in-house for efficient and accelerated characterization and release, including rcAAV, potency, and more.
Once signed does Forge have a dedicated client team?
Yes, each client is assigned a dedicated team for their program. This team is anchored by a Client Relations Manager, a Project Manager, and a Technical Sales & Scientific Advisor, who will support you throughout your entire manufacturing journey at Forge, streamlining communication and guiding each step of the process.
Can we transfer our technology in?
Yes, Forge offers collaborative and systematic full technology transfer capabilities. We support tech transfers for a wide range of viral vectors, including custom viral classes as well as commonly used classes like AAV, lentivirus, baculovirus, and more. Additional key advantages of partnering with Forge for tech transfer include our deep expertise, flexibility in customizing services to fit your unique needs, and access to a facility with a vast array of development and production scales for your program.
What scales do you offer across research-grade, process development, toxicology, engineering, and GMP manufacturing?
We offer AAV production across every stage, including: research-grade (1–40L), process development (1–1,000L), toxicology (50–1,000L), and engineering & GMP manufacturing (50–5,000L).

Talk with Our Client Development Team
We’ve anticipated the challenges so you don’t have to face them alone. Any stage. Any serotype. Built around your journey.
Hot off the Forge
-
Affinia Therapeutics and Forge Biologics Announce AAV cGMP Manufacturing Partnership
“We’re proud to support Affinia’s vision of bringing hope to patients affected by cardiomyopathy through their innovative gene therapy.”
-
Forge Biologics Announces the FUEL™ AAV Manufacturing Platform
FUEL™ platform can achieve a 2-6x increase in productivity compared to industry standard, and includes pEMBR 2.0™ Ad helper and modified rep/cap plasmids.
-
Muscular Dystrophy Association and Forge Biologics Announce AAV Development and Manufacturing Partnership
“Forge has proven to be a trusted partner to gene therapy innovators, advancing many critical programs for rare diseases” Sharon Hesterlee, Ph.D., CRO at the MDA.
-
Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation
Designation grants Forge’s FBX-101 therapy access to enter the Innovative Licensing and Access Pathway (ILAP).